longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Editas Medicine

EDIT

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -5.58, below the reasonable range, cheaper than 95.4% of the time in the past 3 years, and the industry ranks 382/602, the industry Median -2.33.

-5.58xP/E
$2.69Stock price
$-0.48Earnings per share
-5.58xP/E
Stock price$2.69Earnings per share$-0.48

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-1.53x
Typical range
-3.84x–-0.84x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-57.93x148.77%$187.69B
MRNAUSModerna
-23.07x15.47%$72.70B
CSLLYUSCSL Limited
-23.25x--$59.96B
NTRAUSNatera
-292.86x10.38%$56.33B
RVMDUSRevolution Medicines
-23.12x63.53%$40.88B
ROIVUSRoivant Sciences
-99.89x146.49%$26.60B
INSMUSInsmed
-29.52x74.48%$25.84B
BNTXUSBioNTech SE
-12.63x18.23%$24.73B
SMMTUSSummit Therapeutics
-15.33x19.45%$13.12B
BBIOUSBridgebio Pharma
-18.57x28.57%$12.85B
MDGLUSMadrigal Pharma
-36.46x50.86%$11.85B
TWSTUSTwist Bioscience
-76.32x24.61%$10.43B
KYMRUSKymera Therapeutics
-32.05x4.94%$9.60B
ARWRUSArrowHead Pharma
-29.56x36,308.30%$9.46B
CYTKUSCytokinetics
-10.23x6.37%$9.15B
IBRXUSImmunityBio
-9.22x152.63%$9.15B
PCVXUSVaxcyte
-7.90x48.80%$8.41B
ABVXUSAbivax SA
-17.62x20.86%$8.20B
PRAXUSPraxis Precision Medicines
-23.23x3.05%$7.88B
SYREUSSpyre Therapeutics
-51.76x47.81%$7.77B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.